8-K

UNITED STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C.

20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 31, 2024

Immunome,

Inc.

(Exact name of registrant as specified in itscharter)

Registrant’s

telephone number, including area code: (610) 321-3700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b)of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Promotion of Max Rosett and CompensatoryGrant

On January 31, 2024, the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) promoted Max Rosett, the Company’s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer (the “Promotion”). In connection with the Promotion, and based on a review of compensatory arrangements of companies in the Company’s peer group and advice from the Company’s compensation consultant, the Board increased Mr. Rosett’s annual base salary to $425,000 and granted Mr. Rosett an option to purchase 175,000 shares of the Company’s common stock (the “Option”) in accordance with the Company’s 2020 Equity Incentive Plan. The Option has an exercise price per share of $16.57, which was the closing price of the Company’s common stock on the Nasdaq Capital Market on the date of grant. The Option will vest as to 25% of the shares on the one-year anniversary of the grant date with the remaining shares vesting in 36 equal monthly installments thereafter, subject to Mr. Rosett’s continuous service through each vesting date.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.